Results 1-20 of 155 for pfizer

Written Answers — Health: Phenytoin (13 December 2012)

Norman Lamb: ...in the national health service and the manufacturer about the recent increase in the price of phenytoin capsules, following the acquisition of the marketing authorisation by Flynn Pharma Ltd from Pfizer and the effects on NHS budgets.

Previous Business – Lords: Select Committee (20 November 2012)

Science and Technology: Regenerative medicine. 10:30 am; Room 4, Palace of Westminster
Witnesses: (at 10.40am) Dr Ruth McKernan, Chief Scientific Officer of the Neusentis Unit, Pfizer; Professor Chris Mason, Professor of Regenerative Medicine Bioprocessing, UCL; Michael Hunt, Chief Executive Officer, ReNeuron; and (at 11.40am) Navid Malik, Head of Life Sciences Research, Cenkos Security; Nigel Pitchford, Managing Director of Healthcare, Imperial Innovations; and Dr Steven Dyson, Partner...

Written Answers — Health: Phenytoin (8 November 2012) See 1 other result from this answer

Andrew Stunell: ...of State for Health (1) what estimate he has made of the additional cost to the NHS of the repricing of the epanutin form of phenytoin consequent upon its distribution being transferred from Pfizer to Flynn Pharma; and if he will make a statement; (2) what representations he has received on the decision by Pfizer to transfer the marketing and distribution of the epanutin form of...

Business of the House: Growth and Infrastructure Bill (5 November 2012)

Charlie Elphicke: ...is clamouring for infrastructure to be put in place. For example, the east Kent access extension of the A256 in my constituency cost public funds £87 million, but the contribution from the business that was clamouring for it—Pfizer, which has a plant in Sandwich—was only about £1.6 million. Business is making a very small contribution. We should be rather more robust...

Written Answers — Health: Chemicals: Health Hazards (22 October 2012)

Anna Soubry: ... None   Lloyds TSB Shareholder       National Grid Shareholder               Dr Peter Greaves Actelion Pharmaceuticals Ltd, Allschwil, Switzerland Consultant None None   Arena Pharmaceuticals, Inc., San Diego, California         Astellas Pharma Europe Ltd    ...

Neglected Tropical Diseases (26 June 2012)

Jeremy Lefroy: ...of mebendazole to 200 million tablets every year—again, to tackle worms. Novartis is continuing its commitment to providing multi-drug therapy against leprosy in a final push against the disease. Pfizer will continue its donation of drugs for blinding trachoma until at least 2020, as well as donating the drug and a placebo for a study on the reduction in mortality of children treated...

Economy: Growth — Motion to Take Note (21 June 2012)

Baroness Sharp of Guildford: .... Yet it is the availability of these highly trained and highly skilled workers that attracts high-value-added foreign investment, such as that in the pharmaceutical industry, and which-note the position of Pfizer-will leave us if we do not maintain the training of a large number of highly qualified people. We may well be ring-fencing science in relation to other public expenditure but we...

Pharmaceutical Industry (21 March 2012) See 4 other results from this debate

Norman Lamb: ...company to secure its support at this very difficult time for the employees affected. The hon. Lady reflected on the closure of AstraZeneca’s Charnwood site in 2010 and the scaling back of Pfizer’s Sandwich site last year, which involved some 1,200 and 2,400 direct jobs respectively. Decisions on how best to respond have to be based to some extent on the economic impact, time...

[Mr David Amess in the Chair] — Backbench Business — UK Trade and Investment (15 March 2012) See 1 other result from this debate

Laura Sandys: ...involved in that than UKTI. I am therefore very pleased we are having this debate today. For certain personal and constituency reasons, I am particularly interested in UKTI, not least because, a year ago, Pfizer—one of my largest employers—decided to withdraw many of its staff. It is therefore absolutely crucial for me and my constituency to understand more about how UKTI...

Backbench Business: Charging for Access to Parliament (15 March 2012)

Nadine Dorries: ...that. Let me turn to waste in general, which many Members have mentioned. In my previous life, before I became a Member of Parliament, I worked for organisations such as SmithKline Beecham, Pfizer, Shell and Coca Cola-Schweppes. All those organisations, along with many other big corporations, had subsidised canteens and restaurants. The reason they were subsidised was that the overhead...

Oral Answers to Questions — Treasury: Topical Questions (6 March 2012)

Damian Collins: Will the Chancellor join me in welcoming today’s report from the east Kent enterprise zone that nearly 1,000 jobs have already been created on the former Pfizer site? What assessment has the Treasury made of the positive impact of tax credits for video game production and high-end TV production in the UK to mirror the success of the film tax credit, which has helped to secure...

Oral Answers to Questions — Business, Innovation and Skills: Business Growth (2 February 2012)

David Willetts: My hon. Friend is absolutely right. Of course, this week is the first anniversary of the announcement by Pfizer that it was planning to close completely its facility at Sandwich. That will now be transformed into a research and business park, not least thanks to the excellent efforts of my hon. Friend. Indeed, Pfizer will be an anchor tenant employing, we believe, 750 Pfizer staff. That shows...

Oral Answers to Questions — Prime Minister: Engagements (1 February 2012) See 1 other result from this debate

Laura Sandys: Thank you, Mr Speaker. A year ago, I asked the Prime Minister for help when the announcement was made of the Pfizer closure in Sandwich. Does he agree that the support and help from his Ministers, which delivered us an enterprise zone and £40 million for jobs in east Kent, have ensured that we are still a leading centre for life sciences?

Chancellor of the Exchequer: The Economy (6 December 2011)

Charlie Elphicke: ...business park. Money was too often wasted. Now we have a local enterprise partnership that has already created an enterprise zone, which is important to a community that experienced difficulties after Pfizer decided to run down its research in the United Kingdom. That is real progress. Our area has benefited from massive activism. The fast train service to Deal and Sandwich will help to...

Life Sciences — Statement (6 December 2011)

Baroness Thornton: ...that one of our criticisms of this Government is we believe that they have allowed the momentum that we established behind promoting this industry to fall away. Indeed, the unexpected closure of Pfizer earlier this year exposed the Government asleep at the wheel and was a wake-up call. Therefore, to some extent we see this as the Government playing catch-up but it is nevertheless an...

Chancellor of the Exchequer: Registration of Commercial Lobbying Interests (6 December 2011)

John Cryer: ...lobbies on behalf of Benenden and Nuffield; Grayling lobbies on behalf of Cambian, GE Healthcare and Nuffield; Lexington Communications lobbies on behalf of Bupa, GlaxoSmithKline Beecham, Novartis and Pfizer; and MHP Communications lobbies on behalf of Ellipse, IMS Health, Lundbeck, Roche, Grünenthal, Hoffman-La Roche and Janssen-Cilag. Incidentally, one special adviser at the...

Oral Answers to Questions — Communities and Local Government: Life Sciences (5 December 2011) See 1 other result from this debate

Andy Burnham: ...effect of the unnecessary reorganisation of the NHS, particularly the disintegration of the strategic health authorities, which played a role in promoting research. The unexpected closure of Pfizer earlier this year exposed a Government asleep at the wheel and was a wake-up call, and now we see a Government playing catch-up. Although we welcome their belated recognition of the importance...

Opposition Day — [Un-allotted Day]: Economic Growth and Employment (23 November 2011)

Gordon Marsden: ...of connection between business, further education, higher education and small employers that had been built up to boost growth in the English regions. We saw the cost of their hasty abolition when Pfizer announced the closure of its Sandwich plant in February. The South East England Development Agency had previously been able to act swiftly with a task force to help those affected to find...

Written Answers — Business, Innovation and Skills: Research: Expenditure (14 November 2011)

David Willetts: ...locations for commercial and academic R&D and we have the fourth highest concentration of the world's top 1,400 international companies for R&D expenditure, including companies such as Rolls-Royce, Ford, Pfizer, Airbus, Eli Lilly, Eisai, Nokia, Syngenta, Merck and Motorola. And the UK is Europe's most successful country in attracting research-driven inward investment. We are also...

Oral Answers to Questions — Communities and Local Government: Topical Questions (31 October 2011)

Eric Pickles: ...am delighted that the regional growth fund is helping investor technology, and we are seeing the start-up of a local enterprise partnership at the Sandwich site to deal with those questions relating to Pfizer.